Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 7/20 | 0.36 |
| ▸ | IGF1R | P08069 | 2/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.32 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.32 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | FLT4 | P35916 | 1/20 | 0.30 |
| ▸ | MERTK | Q12866 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2268687 | 0.90 | BRD4 (0.38) | PDE4BBRD4IGF1RSLC22A12KARS1 | |
| SCHEMBL2270579 | 0.84 | NPY5R (0.41) | PDE4BBRD4IGF1RMERTK | |
| SCHEMBL2266719 | 0.83 | TRPV1 (0.42) | PDE4BBRD4IGF1RSLC22A12IDO1 | |
| SCHEMBL2268242 | 0.82 | MERTK (0.45) | BRD4MERTK | |
| SCHEMBL2267824 | 0.80 | PDE4B (0.41) | PDE4BIGF1RSLC22A12AKR1C1KARS1 | |
| SCHEMBL2267684 | 0.79 | KMT2A (0.44) | PDE4BBRD4 | |
| SCHEMBL2267763 | 0.78 | PDE4B (0.41) | PDE4BIGF1RSLC22A12AKR1C1KARS1 | |
| SCHEMBL2268972 | 0.78 | AXL (0.42) | BRD4MERTK | |
| SCHEMBL2269303 | 0.77 | BRD4 (0.39) | PDE4BBRD4SLC22A12AKR1C1APP | |
| SCHEMBL2268330 | 0.77 | PDE4B (0.66) | PDE4BIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989463-B2 | Biccyclic compounds as GATA modulators | DR. REDDY'S LABORATORIES LIMITED (IN) | 2011-08-02 | — | — | US | claimed |
| US-20100144731-A1 | Novel Biccyclic Compounds As GATA Modulators | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | claimed |
| WO-2010028174-A1 | NOVEL BICCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-03-11 | — | — | WO | claimed |
| US-7989463-B2 | Biccyclic compounds as GATA modulators | DR. REDDY'S LABORATORIES LIMITED (IN) | 2011-08-02 | — | — | US | disclosed |
| US-20100144731-A1 | Novel Biccyclic Compounds As GATA Modulators | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| WO-2010028174-A1 | NOVEL BICCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144731-A1 | Novel Biccyclic Compounds As GATA Modulators | GATAD2A, GATAD2B, RUNX1 | PDE4B 1568/4885BRD4 33/4885IGF1R 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.